Merck KGaA Names Kai Beckmann as New CEO for May 2026

Merck KGaA has appointed Kai Beckmann as its new CEO, effective from May 2026. Beckmann currently serves as President of Bundesarbeitgeberverband Chemie eV and Chief Executive Officer-Electronics at Merck KGaA. He will succeed Stefan Oschmann, who has been leading the company since 2016. Beckmann brings extensive experience in the chemical industry and will oversee the company's pharmaceutical and chemical divisions.

Merck KGaA, a leading global pharmaceutical and chemical company, has announced the appointment of Kai Beckmann as its new CEO. Beckmann will take over the position from Stefan Oschmann, who has been leading the company since 2016, effective from May 2026 Merck Says Kai Beckmann To Succeed Belén Garijo As Chair Of The Executive Board And CEO Of Merck As Of May 2026^[1]. Beckmann currently serves as President of Bundesarbeitgeberverband Chemie eV and Chief Executive Officer-Electronics at Merck KGaA.

The appointment comes as Merck continues to expand its portfolio and pipeline, with recent acquisitions and strategic moves to bolster its position in the market. In July 2025, Merck announced the acquisition of Verona Pharma for approximately $10 billion, adding Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), to its growing cardio-pulmonary pipeline Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade^[2]. This acquisition aligns with Merck's science-led business development strategy and reflects its commitment to delivering innovative treatments to patients.

Beckmann's extensive experience in the chemical industry and his current role as CEO-Electronics at Merck KGaA position him well to oversee the company's pharmaceutical and chemical divisions. His appointment follows a successful tenure by Belén Garijo, who is set to complete her role as planned by the end of April 2026 Merck Says Kai Beckmann To Succeed Belén Garijo As Chair Of The Executive Board And CEO Of Merck As Of May 2026^[1]. Garijo's successor, Kai Beckmann, will become Deputy CEO effective immediately and continue in his role as CEO of Electronics until a successor is announced.

The appointment of Kai Beckmann underscores Merck's commitment to leadership continuity and strategic growth. As the company navigates the evolving landscape of the pharmaceutical and chemical industries, Beckmann's leadership will be crucial in driving innovation and maintaining Merck's position as a premier global healthcare company.